# Journey Medical Corp: overview

DERM · Nasdaq · CIK 1867066 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/derm.md) · [Financials](/companies/derm/financials.md) · [Filings](/companies/derm/filings.md) · [Insiders](/companies/derm/insiders.md)

Latest reported revenue: [$17.8m](/filings/0001104659-26-094948.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-094948).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.6](/filings/0001104659-25-110457.md) | [12.6 d](/filings/0001104659-26-034629.md) | [13.1](/filings/0001104659-26-060297.md) | [15.0](/filings/0001104659-26-094948.md) | [17.0](/filings/0001104659-25-110457.md) | [16.1 d](/filings/0001104659-26-034629.md) | [15.9](/filings/0001104659-26-060297.md) | [17.8](/filings/0001104659-26-094948.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(19.8%)](/filings/0001104659-25-110457.md) | [17.7% d](/filings/0001104659-26-034629.md) | [(25.3%)](/filings/0001104659-26-060297.md) | [(19.2%)](/filings/0001104659-26-094948.md) | [(9.0%)](/filings/0001104659-25-110457.md) | [(2.8%) d](/filings/0001104659-26-034629.md) | [(9.4%)](/filings/0001104659-26-060297.md) | [2.6%](/filings/0001104659-26-094948.md) |
| Net margin | % | [(16.3%)](/filings/0001104659-25-110457.md) | [12.1% d](/filings/0001104659-26-034629.md) | [(31.0%)](/filings/0001104659-26-060297.md) | [(25.3%)](/filings/0001104659-26-094948.md) | [(13.6%)](/filings/0001104659-25-110457.md) | [(7.8%) d](/filings/0001104659-26-034629.md) | [(14.0%)](/filings/0001104659-26-060297.md) | [(1.7%)](/filings/0001104659-26-094948.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001104659-25-110457.md) | not reported | [(0.18)](/filings/0001104659-26-060297.md) | [(0.16)](/filings/0001104659-26-094948.md) | [(0.09)](/filings/0001104659-25-110457.md) | not reported | [(0.08)](/filings/0001104659-26-060297.md) | [(0.01)](/filings/0001104659-26-094948.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [63.1](/filings/0001410578-23-000485.md) | [71.0](/filings/0001410578-24-000347.md) | [59.7](/filings/0001410578-25-000490.md) | [55.1](/filings/0001104659-26-034629.md) | [61.2](/filings/0001104659-26-034629.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(55.2%)](/filings/0001410578-23-000485.md) | [(38.8%)](/filings/0001410578-24-000347.md) | [(3.5%)](/filings/0001410578-25-000490.md) | [(24.8%)](/filings/0001104659-26-034629.md) | [(13.3%)](/filings/0001104659-26-034629.md) |
| Net margin | % | [(69.7%)](/filings/0001410578-23-000485.md) | [(41.7%)](/filings/0001410578-24-000347.md) | [(6.5%)](/filings/0001410578-25-000490.md) | [(26.6%)](/filings/0001104659-26-034629.md) | [(18.7%)](/filings/0001104659-26-034629.md) |
| Diluted EPS | $ per share | [(4.32)](/filings/0001410578-23-000485.md) | [(1.69)](/filings/0001410578-24-000347.md) | [(0.21)](/filings/0001410578-25-000490.md) | [(0.72)](/filings/0001104659-26-034629.md) | [(0.47)](/filings/0001104659-26-034629.md) |
| Free cash flow | $m | not reported | [(33.5)](/filings/0001410578-24-000347.md) | [0.2](/filings/0001410578-25-000490.md) | [(24.1)](/filings/0001104659-26-034629.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/derm/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $20.2m | 2,858,930 |  | Added +725,560 |
| [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $11.4m | 1,610,000 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.8m | 675,185 |  | Reduced −406,895 |
| [PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.](/funds/1238990.md) | 2026-06-30 | $3.8m | 536,000 |  | New +536,000 |
| [Pale Fire Capital SE](/funds/1922318.md) | 2026-06-30 | $3.7m | 528,584 |  | Added +46,597 |
| [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $2.5m | 350,000 |  | Reduced −610,000 |
| [Summit Financial, LLC](/funds/1765536.md) | 2026-06-30 | $2.5m | 346,748 |  | Reduced −33,059 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.3m | 320,021 |  | New +320,021 |
| [Diametric Capital, LP](/funds/1719087.md) | 2026-06-30 | $2.1m | 295,663 |  | Added +99,251 |
| [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $1.8m | 251,436 |  | Unchanged |

## Recent filings

[All 224 filings](/companies/derm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-12 | 20:40 ET | [10-Q](/filings/0001104659-26-094948.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094948 |
| 2026-08-12 | 20:05 ET | [8-K](/filings/0001104659-26-094862.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094862 |
| 2026-06-26 | 00:01 ET | [8-K](/filings/0001104659-26-077888.md) | 5.07 Shareholder vote results | 0001104659-26-077888 |
| 2026-05-13 | 20:33 ET | [10-Q](/filings/0001104659-26-060297.md) | Quarterly report, period 2026-03-31 | 0001104659-26-060297 |
| 2026-05-13 | 20:06 ET | [8-K](/filings/0001104659-26-060232.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-060232 |
| 2026-04-30 | 20:06 ET | [DEF 14A](/filings/0001104659-26-052883.md) | Proxy statement, period 2026-06-24 | 0001104659-26-052883 |
| 2026-04-21 | 21:20 ET | [8-K](/filings/0001104659-26-046158.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-046158 |
| 2026-03-26 | 21:35 ET | [10-K](/filings/0001104659-26-034629.md) | Annual report, period 2025-12-31 | 0001104659-26-034629 |
| 2026-03-25 | 20:05 ET | [8-K](/filings/0001104659-26-034506.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-034506 |
| 2025-11-12 | 21:41 ET | [10-Q](/filings/0001104659-25-110457.md) | Quarterly report, period 2025-09-30 | 0001104659-25-110457 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034629.md), filed Mar 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c0d79a3a-6a3f-487b-9043-7139c201837e)

## About the filer

- CIK: 1867066
- Tickers: DERM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.